Checkpoint kinase 1 is activated and promotes cell survival after exposure to sulphur mustard by Jowsey, Paul & Blain, Peter G.
Northumbria Research Link
Citation: Jowsey, Paul and Blain, Peter G. (2015) Checkpoint kinase 1 is activated and promotes cell 
survival after exposure to sulphur mustard. Toxicology Letters, 232 (2). pp. 413-421. ISSN 0378-4274 
Published by: Elsevier
URL: https://doi.org/10.1016/j.toxlet.2014.11.013 <https://doi.org/10.1016/j.toxlet.2014.11.013>
This  version  was  downloaded  from  Northumbria  Research  Link: 
http://nrl.northumbria.ac.uk/id/eprint/43606/
Northumbria University has developed Northumbria Research Link (NRL) to enable users to access 
the University’s research output. Copyright © and moral rights for items on NRL are retained by the 
individual author(s) and/or other copyright owners.  Single copies of full items can be reproduced, 
displayed or performed, and given to third parties in any format or medium for personal research or 
study, educational, or not-for-profit purposes without prior permission or charge, provided the authors, 
title and full bibliographic details are given, as well as a hyperlink and/or URL to the original metadata 
page. The content must not be changed in any way. Full items must not be sold commercially in any  
format or medium without formal permission of the copyright holder.  The full policy is available online: 
http://nrl.northumbria.ac.uk/pol  i cies.html  
This  document  may differ  from the  final,  published version of  the research  and has been made 
available online in accordance with publisher policies. To read and/or cite from the published version 
of the research, please visit the publisher’s website (a subscription may be required.)
                        
  
Checkpoint kinase 1 is activated and promotes cell survival after  
exposure to sulphur mustard  
 
 
 
 
Paul A Jowsey
a
 and Peter G Blain 
 
 
Medical Toxicology Centre, Wolfson Unit, Newcastle University, Newcastle upon Tyne, 
NE2 4AA 
 
 
 
 
 
a
 To whom correspondence should be addressed 
e-mail:   p.a.jowsey@ncl.ac.uk 
Tel:  +44-191-2228537 
Fax:  +44-191-2226442 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
Sulphur mustard (SM) is a vesicating agent that has been used several times as a weapon 
during military conflict and continues to pose a threat as an agent of warfare/terrorism.  After 
exposure, SM exerts both acute and delayed long-term toxic effects principally to the skin, 
eyes and respiratory system.  These effects are thought to be mediated, at least in part, by 
direct interaction of SM with DNA, forming a myriad of DNA lesions and initiating effects 
on cell cycle and cell death pathways.  Previous studies have demonstrated that a complex 
network of cellular DNA damage response pathways are utilised in cells exposed to SM, 
consistent with SM causing multiple forms of DNA damage.  The present study focused on 
the role of Checkpoint kinase 1 (CHK1), a protein with putative roles in homologous 
recombination repair, p53 activation and the initiation of cell cycle checkpoints after certain 
forms of DNA damage.  The data showed that SM caused robust activation of CHK1, 
monitored by multi-site phosphorylation analysis and that this activation was dependent on 
the ataxia telangiectasia and Rad3-related (ATR) protein kinase.  Furthermore, specific 
inhibition of CHK1 increased SM toxicity in multiple human cell lines, with concomitant 
increases in markers of apoptosis, DNA damage and mitosis.  Finally, the effect of CHK1 
inhibition on SM toxicity was much more marked in cells with non-functional p53. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Exposure to sulphur mustard [SM, bis(2-chloroethyl) sulphide)] results in acute toxicity to 
the skin and mucosal surfaces of the eyes and respiratory system (Balali-Mood and Hefazi, 
2006; Saladi et al., 2006), with symptoms ranging from mild irritation to severe inflammation 
or blistering developing over the course of several hours.  After high level exposure, SM can 
become systemic and exert toxic effects on the hematopoietic system, causing 
immunosuppression and vulnerability to secondary infections (Balali-Mood and Hefazi, 2005; 
Ghabili et al., 2011).  There is also increasing evidence of delayed long-term health effects 
after a single exposure to SM and apparent recovery from the initial acute toxicity (Balali-
Mood et al., 2005; Mahmoudi et al., 2005).  These health effects include skin irritation, 
chronic obstructive pulmonary disease and an increased incidence of certain cancers, 
particularly those affecting the respiratory system.  The precise mechanisms mediating the 
acute and long-term toxicity of SM remain to be elucidated and there is currently no 
treatment option in the event of an exposure.  
SM is a bifunctional alkylating agent with mutagenic and carcinogenic properties 
(Ashby et al., 1991).  The reaction of SM with DNA is initiated by the formation of a highly 
reactive sulphonium ion.  This intermediate ion forms readily under aqueous conditions, 
hence the particular vulnerability of moist tissues (e.g. eye and respiratory tract) to SM 
toxicity.  The most abundant DNA lesion after SM exposure is the monoadduct N7-
hydroxyethyl thioethyl guanine (N7-HETE-G), constituting around 60% of total DNA 
adducts (Fidder et al., 1994), although other monoadducts are also formed.  These adducts are 
prone to depurination, resulting in the formation of abasic sites.  DNA crosslinks (both inter 
and intrastrand) caused by SM constitute only 16% of total DNA lesions but are responsible 
for the high toxicity of this agent.  This is clearly demonstrated by an approximate 100-fold 
increase in the toxicity of bifunctioinal SM compared to a monofunctional analogue (Jowsey 
et al., 2012).   
Cells respond to genotoxic damage by initiating DNA damage signalling cascades, 
orchestrated by the ataxia telangiectasia mutated (ATM) and ATR protein kinases.  These 
kinases respond to different forms of DNA damage, for example ATM is normally activated 
in the presence of DNA double strand breaks (DSBs), whereas ATR is activated by single 
strand stretches of DNA, formed during the processing of various forms of DNA damage, 
including DNA adducts and crosslinks (Abraham, 2004; Hurley and Bunz, 2007).  Once 
activated, these kinases phosphorylate a wide range of target proteins, including the 
checkpoint kinases CHK1 and CHK2, the tumour suppressor p53 and the histone variant 
H2AX.  Given that SM is able to form a variety of DNA lesions, the pathways and proteins 
involved in the cellular response are likely to be diverse and complex.  Previous studies have 
demonstrated the activation of both ATM and ATR after exposure to SM and monofunctional 
analogues (Jowsey et al., 2012; Tewari-Singh et al., 2010).  The present study focused on the 
role of CHK1 in response to SM.  The activation of CHK1 has been demonstrated after 
various DNA damaging agents, including ultra-violet radiation, ionising radiation and 
mono/bifunctional alkylating agents (Patil et al., 2013; Zhang and Hunter, 2014).  The 
mechanism of activation involves ATR-dependent phosphorylation of CHK1 at Ser317 and 
Ser345 (Zhao and Piwnica-Worms, 2001).  It has been proposed that these phosphorylation 
events relieve the inhibiton normally imposed by the c-terminal regulatory domain of CHK1 
on the n-terminal catalytic domain.  Mutation of Ser317 or 345 significantly inhibits CHK1 
activation, leads to inefficient checkpoint activation and sensitivity to certain genotoxic 
agents, particularly those that interfere with DNA replication (Capasso et al., 2002; Walker et 
al., 2009).  Subsequent to Ser317/345 phosphorylation, it has been demonstrated that CHK1 
undergoes intramolecular autophosphorylation on Ser296 (Clarke and Clarke, 2005; Kasahara 
et al., 2010).  Whilst phosphorylation of this site has a negligible effect on CHK1 activity, it 
is important in regulating mitotic entry after UV-induced DNA damage, via association with 
the Cdc25A phosphatase (Kasahara et al., 2010).  In unperturbed cells, CHK1 regulates 
multiple aspects of cell cycle progression, including DNA replication, mitotic entry and the 
mitotic spindle checkpoint.  After DNA damage, CHK1 regulates cell cycle arrest at the G1/S 
and G2/M transitions as well as during DNA replication, principally by phosphorylation of 
the Cdc25 family of phosphatases, resulting in relocalization and/or degradation of Cdc25 
(Patil et al., 2013; Zhang and Hunter, 2014). Collectively, the Cdc25 phosphatases act to 
remove inhibitory phosphate groups and thus activate kinases that drive cell cycle 
progression.  CHK1 has also been implicated in chromatin remodelling, an essential 
component of efficient DNA repair, as well as the homologous recombination repair pathway 
(Sorensen et al., 2005). 
 The present study aimed to investigate CHK1 activation and regulation after exposure 
to the bifunctional alkylating agent SM as well as whether CHK1 has a protective role in the 
cellular response to SM.  The data showed that SM caused robust activation of CHK1, with 
ATR-dependent phosphorylation of Ser317 and autophosphorylation of Ser296.  Specific 
inhibition of CHK1 blocked Ser296 autophosphorylation and increased SM toxicity in 
multiple human cell lines, with concomitant increases in markers of apoptosis, DNA damage 
and mitosis.  Finally, the effect of CHK1 inhibition on SM toxicity was more marked in cells 
with non-functional p53. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Materials and methods 
 
2.1. Cell lines, chemicals and treatments 
 Hela, HCT 116, HEK 293, SH-SY5Y and A549 cells were obtained from HPA 
Cultures (Health Protection Agency, Porton Down, UK) and maintained as exponentially 
growing cultures in Dulbecco’s Modified Eagle Medium supplemented with 10% fetal 
bovine serum and 2mM L-glutamine (Sigma).  The CHK1 inhibitor PF 477736 (Tocris 
Bioscience) was prepared at a stock concentration of 50mM in DMSO and added to cells at 
final concentrations ranging from 20-250nM (Blasina et al., 2008).  The ATR inhibitor AZ 20 
(Tocris Bioscience) was prepared at a stock concentration of 50mM in DMSO and added to 
cells at a final concentration of 4M (Foote et al., 2013).  Inhibitors were added to cells 
45min prior to treatment with DNA damaging agents and the DMSO concentration was 
maintained at 0.1% (v/v) in all samples, with no effect on cell viability.  SM was obtained 
from The Defence Science and Technology Laboratories (Dstl, Porton Down, UK) and stored 
at 4°C.  On the day of use, appropriate dilutions were prepared in isopropanol and added to 
culture medium such that the final isopropanol concentration was 0.2% (v/v) in all samples.  
This concentration had no effect on cell viability.  SM treatments were performed in normal 
growth medium containing serum.  This was to ensure that cells retained their proliferative 
capacity during the course of the study.  This is important for mechanistic studies on the 
cellular response to SM as cell proliferation, and DNA replication in particular, are highly 
relevant to the toxic mechanism of SM. 
 
2.2. Cell viability assay  
Cells were seeded in 24-well plates and allowed to adhere overnight.  After treatment 
with 100nM PF 477736 for 45 min, cells in normal growth medium (see 2.1) were treated 
with the indicated concentrations of SM (or isopropanol control for ‘untreated’ cells) for 24-
48h prior to the measurement of cell viability using an MTS-based assay (Promega).  Briefly, 
culture medium was removed and replaced with 300l of medium containing 20% (v/v) of 
MTS reagent.  Cells were incubated at 37
o
C for up to 1hr before the absorbance of each well 
was measured at 490nm.  Data were plotted on graphs, with cell viability at each dose of SM 
being calculated as a % relative to untreated cells (untreated cells designated as 100% 
viability).  Isopropanol alone (0.2% v/v) was not cytotxic.  The significance of the observed 
changes in cell viability were investigated using a paired t-test.  Levels of significance were 
defined as follows: p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***). 
2.3. Western blotting  
After the indicated treatments, cells were washed in cold phosphate buffered saline 
(PBS) before lysis in 1X LDS sample buffer (Invitrogen) containing 5% (v/v) 2-
mercaptoethanol.  Lysates were boiled for 5min prior to sonication to shear the cellular DNA.  
Protein concentrations were determined using Coomassie Bradford Reagent (Pierce 
Biotechnology) and 20g of protein separated on 4-12% bis-tris gels (Invitrogen) using 
MOPS buffer (Invitrogen) at a constant voltage of 180V for 1h.  Proteins were transferred to 
Hybond-C nitrocellulose membrane (GE Healthcare) using an iBlot machine set at 20V for 
13min (Invitrogen).  Gel electrophoresis and transfer were performed at room temperature.  
Membranes were probed using standard protocols, with the following primary antibodies:  
anti-CHK1 phospho-Ser296 (2349), anti-CHK1 phospho-Ser317 (12302), anti-CHK1 (2360) 
anti-PARP-1 (9542), anti-cleaved caspase-3 (9664), anti-caspase-9 (9502), anti-H2AX 
phospho-Ser139 (2577), anti-histone H3 phospho-Ser10 (9701), anti-cdc2(CDK1) phosphor-
Tyr15 (9111) and GAPDH (2118), all from Cell Signalling Technologies.  Membranes were 
then washed in TBST (50mM tris pH 7.6, 150mM NaCl and 0.2% Tween20) followed by 
incubation with the relevant HRP-conjugated secondary antibody.  Membranes were washed 
thoroughly with TBST and visualised using enhanced chemiluminescence (ECL Plus, GE 
Biosciences).  Images were captured using a Syngene G:Box gel documentation system and 
bands quantified using ImageJ software (http://imagej.nih.gov/ij/).  Data were collected from 
three independent experiments.  For quantification of CHK1 phosphorylation, band 
intensities were normalised to levels of total CHK1 protein.  For quantification of all other 
bands, levels were normalised to the levels of GAPDH. 
 
 
 
 
 
 
 
 
 
 
 
3. Results 
3.1.  Activation of CHK1 in cells treated with SM 
 CHK1 is activated by multi-site phosphorylation mediated by ATM/ATR, resulting in 
functionally important autophosphorylation at Ser296.  To investigate whether CHK1 was 
activated by SM, a range of human cell lines were exposed to SM for 5h prior to analysis of 
CHK1 phosphorylation.  Multiple human cells were studied to exclude the possibility of cell 
line-specific effects.  In addition, previous studies had demonstrated robust activation of 
DNA damage signalling events in these cell lines after treatment with 25M SM for 5h.  At 
this dose and time point there was no evidence of cytotoxicity.  The sites analysed were 
Ser317 and Ser296 (autophosphorylation site).  As shown in Figure 1, both sites were 
robustly and markedly phosphorylated after exposure to SM.  For subsequent studies 
investigating the regulation and functional significance of CHK1 activation, we used two cell 
lines which demonstrated robust CHK1 phosphorylation and had wild type p53 status and 
intact p53 responses (HCT 116 and A549).  In addition, A549 cells are derived from lung 
tissue and thus have relevance in terms of sites of SM exposure. 
 
3.2  ATR activates CHK1 after exposure to SM 
 To investigate whether ATR was involved in the activation of CHK1, a specific 
kinase inhibitor (AZ 20) was used.  Studies showed that 4M AZ 20 was able to block UV-
induced activation of ATR and this concentration was therefore used in this study (data not 
shown).  HCT 116 and A549 cells were pre-treated with AZ 20 before exposure of cells to 
25M SM for 5h and analsyis of CHK1 activation using Western blotting.  As shown in 
Figure 2A and 2B, AZ 20 virtually abolished the SM-induced phosphorylation of CHK1 at 
both Ser296 and Ser317 in both HCT 116 and A549 cells.  These data suggest that ATR is 
required for CHK1 activation after exposure to SM and that ATR-mediated phosphorylation 
of Ser317 is necessary before CHK1 can autophosphorylate on Ser296. 
 
3.3. PF 477736 blocks CHK1 activation after exposure to SM 
 To investigate the functional significance of CHK1 activation after exposure to SM, a 
specific inhibitor of CHK1 was used (PF 477736).  To establish the most appropriate dose of 
PF 477736 to use in these studies, CHK1 phosphorylation was investigated after UV 
exposure (widely known to activate CHK1) in cells treated with 20-250nM PF 477736.  As 
shown in Figure 3A, UV caused a marked increase in CHK1 phosphorylation at both Ser296 
and 317.  Treatment with PF47736 inhibited Ser296 phosphorylation at all doses used but had 
little or no effect on the ATR target site Ser317.  Based on the results in Figure 3A, 100nM 
PF 477736 was selected as the most appropriate dose to completely block CHK1 activity.  To 
demonstrate that this dose of PF 477736 was able to block SM-induced CHK1 activation, 
cells were pre-treated with 100nM PF 477736 prior to treatment with SM for 5h and analysis 
of CHK1 activation using Western blotting.  As shown in Figure 3B and 3C, SM caused a 
marked increase in both Ser296 and Ser317 phosphorylation of CHK1.  Consistent with the 
data after UV treatment, 100nM PF 477736 completely blocked CHK1 activity, assessed by 
autophosphorylation on Ser296, but did not inhibit ATR-mediated phosphorylation on 
Ser317.  Together, these data show that the kinase activity of CHK1 can be completely 
blocked by 100nM PF 477736 
 
3.4. Inhibition of CHK1 increases SM cytotoxicity 
 To investigate the functional significance of CHK1 activation after exposure to SM, 
the cytotoxicity of SM was measured in cells +/- 100nM PF 477736.  This concentration of 
PF 477736 has previously been shown to completely inhibit CHK1 activation after exposure 
to SM (see Fig. 3B and 3C).  Several human cell lines were pre-treated with 100nM PF 
477736 before treatment with SM and measurement of cell viability using an MTS assay.  
Microscopic inspection of cells revealed high levels of SM-induced cytotoxicity in HEK 293 
cells after 24h.  Therefore, MTS assays were performed in these cells at this time point.  All 
other cells were left for 48h prior to MTS assay.  As shown in Figure 4A, CHK1 inhibition 
(PF 477736) caused a decrease in cell viability at both 10M SM and 25M SM in all cell 
lines tested, compared to cells with active CHK1 (DMSO).  All changes were shown to be 
statistically significant with the exception of A549 at 10M SM (+/- PF 477736).  To 
corroborate these findings and to investigate the mechanism of cytotoxicity, the levels of 
CHK1 phosphorylation and several markers of apoptosis, DNA damage and mitosis were 
measured in Hela cells using Western blotting.  As shown in Figure 4B, SM caused clear 
phosphorylation of CHK1 on Ser296 at both 10M and 25M.  Pre-treatment of cells with 
100nM PF 477736 completely blocked CHK1 autophosphorylation on Ser296, thus 
confirming that CHK1 activity was efficiently inhibited in these cells.  For markers of 
apoptosis, the cleavage of PARP-1, caspase-3 and caspase-9 were measured.  For DNA 
damage, the level of H2AX Ser139 phosphorylation was measured.  This is a well-validated 
marker for DNA damage, in particular DNA double strand breaks.  Our previous studies 
demonstrated H2AX Ser139 phosphorylation (and the formation of H2AX p-Ser139 nuclear 
foci) after SM, hence the use of H2AX Ser139 as a marker of DNA damage in the current 
study (Jowsey et al., 2010).  For quantification of mitosis, levels of histone H3 Ser10 
phosphorylation were measured.  To further investigate the progression of cells from G2 
phase into mitosis, the phosphorylation of cyclin dependent kinase 1 (CDK1) on Tyr15 was 
measured.  CDK1 activation is required for progression into mitosis and is associated with 
CDC25C-mediated dephosphorylation of CDK1 Tyr15.  As shown in Figure 4B and 4C, all 
markers of apoptosis were increased in CHK1-inhibited cells after exposure to SM compared 
to cells with active CHK1, with a concomitant increase in the levels of DNA damage.  In 
addition, SM treatment caused a marked increase in CDK1 Tyr15 phosphorylation (i.e. 
CDK1 inactivation) and decreased histone H3 Ser10 phosphorylation.  These findings are 
consistent with activation of the G2/M phase checkpoint and the prevention of cells with 
DNA damage entering mitosis.  On the contrary, CHK1 inhibition prevented the SM-induced 
increase in CDK1 Tyr15 phosphorylation (meaning increased CDK1 activity and defective 
G2/M phase checkpoint), resulting in increased levels of histone H3 phosphorylation after 
treatment with SM.  Preliminary studies also demonstrated decreased phosphorylation of 
CDC25C in cells treated with SM+PF 477736 compared to SM alone (data not shown).  
CDC25C is phosphorylated by CHK1 after DNA damage, causing cytoplasmic retention of 
CDC25C and decreased dephosphorylation of CDK Tyr15 and thus decreased activation of 
CDK1. 
 
Together, these data show that inhibition of CHK1 increases the cytotoxicity of SM, with 
concomitant increases in the levels of apoptosis and DNA damage, along with uncontrolled 
progression into mitosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
Sulphur mustard is a highly toxic chemical agent that poses a current threat to both civilian 
and military personnel in the event of a deliberate malicious release.  The precise 
mechanisms mediating the acute and chronic long-term health effects associated with 
exposure to SM are not fully understood and there is currently no therapeutic option for 
exposed individuals.  It is therefore essential to have a detailed understanding of the 
molecular effects that SM has upon a cell as well as the cellular mechanisms involved in 
repairing any damage caused.  This study focused on the cell cycle/DNA damage signalling 
kinase CHK1.  The data demonstrated robust activation of this enzyme after exposure to SM 
in multiple human cell lines.  This activation was found to be mediated by the ATR protein 
kinase.  Specific inhibition of CHK1 increased SM cytotoxicity, concomitant with increased 
markers of apoptosis (cleaved PARP-1/caspase-3/caspase-9), DNA damage (H2AX Ser139) 
and mitosis (phosphorylated histone H3).  Together, these data suggest that CHK1 promotes 
cell survival after exposure to SM, likely via the regulation of DNA repair processes and 
blocking entry of damaged cells into mitosis. 
DNA damage signalling is initiated by the ATM and ATR kinases, which 
phosphorylate and activate the checkpoint kinases CHK1 and CHK2 (Smith et al., 2010).  
Our previous studies have demonstrated the activation of ATM after exposure to SM, 
monitored by measuring phosphorylation of Ser1981, as well as ATR-dependent 
phosphorylation of CHK1 at Ser317 (Jowsey et al., 2012).  Inhibition of ATM slightly 
increased SM cytotoxicity, whilst a marked increase in SM toxicity was observed when both 
ATM and ATR were inhibited.  This highlights the importance of DNA damage signalling 
pathways after exposure to SM.  ATM and ATR play important roles, likely due to the 
variety of DNA lesions induced by SM, including different DNA adducts and crosslinks, 
which will impede DNA replication and activate ATR.  In addition, stalled replication forks 
and processing of DNA crosslinks, result in the generation and DNA DSBs and subsequent 
activation of ATM.  Other studies have shown the activation of ATM and ATR after 
exposure of cells to the monofunctional SM analogue 2-chloroethyl ethyl sulphide (CEES) 
(Jowsey et al., 2009; Tewari-Singh et al., 2010).  Whilst phosphorylation of CHK1 at Ser317 
and Ser345 has been demonstrated after exposure to SM/CEES, no studies have directly 
monitored CHK1 autophosphorylation and thus kinase activation.  The activation of CHK1 
requires multi-site phosphorylation, including Ser317 and Ser345, with mutation of these 
sites markedly reducing CHK1 kinase activity (Capasso et al., 2002; Walker et al., 2009).  
Subsequent to Ser317/345 phosphorylation, CHK1 undergoes intramolecular 
autophosphorylation on Ser296 (Clarke and Clarke, 2005).  Whilst this modification is not 
essential for the activation of CHK1, it does allow the kinase activity of CHK1 to be 
conveniently monitored using phospho-specific antibodies.  Consistent with the mechanism 
of CHK1 activation described above, the present study showed that the inhibition of ATR 
blocked both CHK1 Ser317 phosphorylation and Ser296 autophosphorylation after exposure 
to SM.  In addition, specific inhibition of CHK1 did not decrease phosphorylation of Ser317 
but totally blocked autophosphorylation on Ser296 after exposure to SM. 
Whilst phosphorylation of CHK1 at Ser296 is not essential for the activation of CHK1, 
it does have important functional significance.  Expression of a CHK1 Ser296Ala mutant in 
CHK1-deficient cells results in inefficient G2/M arrest after UV and uncontrolled progression 
into mitosis (Kasahara et al., 2010).  This is consistent with our observation that inhibition of 
CHK1, and thus loss of Ser296 phosphorylation, resulted in markedly increased histone H3 
phosphorylation (a marker of mitosis) after exposure to SM.  This finding was further 
supported by decreased CDC25C Ser216 phosphorylation (data not shown) and decreased 
CDK1 Tyr15 phosphorylation in cells treated with SM+PF 477736 compared to SM alone.  
These data strongly suggests that PF 477736 prevents CHK1-mediated phosphorylation of 
CDC25C.  CDC25C thus remains in the nucleus and dephosphorylates CDK1 Tyr15, 
resulting in CDK1 activation and unwanted progression of cells into mitosis.  Our data also 
demonstrated that CHK1 inhibition increased SM toxicity in multiple human cell lines, 
concomitant with increased levels of multiple apoptosis markers.  This could be a result of 
the uncontrolled progression of DNA damaged cells into mitosis and subsequent ‘mitotic 
catastrophe’.  Other studies have demonstrated that inhibition of CHK1 sensitises cells to 
crosslinking agents such as carboplatin and cisplatin, with proposed mechanisms involving 
inefficient G2/M phase arrest (Blasina et al., 2008; Thompson et al., 2012). 
The present study also demonstrated increased levels of histone H2AX Ser139 
phosphorylation in CHK1-inhibited cells after exposure to SM.  Phosphorylation of this 
protein has been demonstrated after multiple genotoxic agents and generally correlates with 
levels of cellular DNA damage.  Our previous studies have demonstrated clear 
phosphorylation of H2AX Ser139 after exposure to SM as well as the formation of H2AX 
nuclear foci, representing sites of DNA DSBs (Jowsey et al., 2010).  The levels of Ser139 
phosphorylation and number of nuclear foci were markedly increased in cells lacking 
homologous recombination repair (HRR).  CHK1 contributes to HRR by phosphorylation of 
RAD51 and promoting the formation of RAD51 filaments on single-stranded DNA, prior to 
strand invasion/exchange with an undamaged sister chromatid (Bahassi et al., 2008; Sorensen 
et al., 2005).  Whilst further studies will be required to verify this, it is likely that CHK1 
inhibition reduces the efficiency of HRR after exposure to SM, resulting in increased levels 
of DSBs, increased H2AX Ser139 phosphorylation and increased cell death.  In addition, 
CHK1 contributes to the s-phase checkpoint as well as the stabilisation of stalled replication 
forks (e.g. at sites of DNA crosslinks) (Smith et al., 2010).  Defects in both of these processes 
(in cells treated with SM+PF 477736) would also result in increased levels of DNA DSBs 
and increased H2AX Ser139 phosphorylation.  Our data also demonstrated that the effect of 
CHK1 inhibition on SM toxicity was most significant in Hela cells, with an approximate 2-
fold increase in SM toxicity observed, compared to cells with active CHK1.  Interestingly, 
these cells lack p53 responses due to Human Papilloma Virus-mediated down-regulation of 
p53, rendering the cells effectively p53 null.  As a result, Hela cells have a defective p53-
mediated G1/S phase arrest, thus allowing SM-damaged cells to progress into S/G2/M phases 
of the cell cycle.  Whilst the lack of G1/S phase arrest alone is likely to increase SM toxicity, 
this effect will be further exacerbated by inhibition of CHK1 and the previously described 
effects on the G2/M checkpoint.  There has been considerable interest in the use of CHK1 
inhibitors in combination therapy for cancer.  For example, given that the majority of tumours 
have mutant p53 and thus lack efficient G1/S-phase arrest, it was hypothesised that inhibition 
of CHK1 (and thus abrogation of S-phase and G2/M checkpoints) would potentiate the 
effects of chemotherapy agents.  A recent study demonstrated that this was not the case, with 
siRNA-mediated knockdown of CHK1 and treatment with irinotecan (a topoisomerase I 
inhibitor) or cisplatin showing similar toxicity in p53-proficient and –deficient cells (Zenvirt 
et al., 2010).  This is in contrast to the present study, where CHK1 inhibition increased SM 
toxicity in all cell lines tested, though by far the greatest effect was observed in Hela cells, 
which do not express p53.  This suggests that cells lacking functional p53 are more sensitive 
to the combined toxic effect of CHK1 inhibition and SM, than cells expressing wild-type p53.  
We are currently investigating whether thus effect is specific to SM or whether is also 
observed in response to clinically relevant compounds related to SM, such as nitrogen 
mustards.  These studies will also be performed in isogenic cell line pairs (+/- p53). 
In order to better understand the toxic mechanism of SM and develop potential 
therapeutic procedures, it is necessary to have a detailed understanding of the cellular 
biochemical changes associated with exposure to this agent.  The present study demonstrated 
robust activation of CHK1 in multiple human cell lines after exposure to SM.  Specific 
inhibition of CHK1 rendered cells more sensitive to SM toxicity with increased levels of 
apoptosis, likely due to defects in homologous recombination repair and premature entry of 
SM-exposed cells into mitosis. 
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Figure Legends 
Fig. 1.  Activation of CHK1 in cells treated with SM.  (A) HCT 116, SH-SY5Y, Hela, A549 
and HEK 293 cells were treated with 25M SM for 5h prior to investigation of CHK1 
activation using Western blotting with the indicated antibodies.  (B) Quantification of the 
Western blot data in (A) using ImageJ software.  Data is presented as level of Ser296 or 
Ser317 normalised to total CHK1 and represents the mean and standard deviation of three 
independent experiments. 
 
Fig. 2.  ATR-dependent activation of CHK1 after exposure to SM. (A) HCT 116 and A549 
cells were treated with 4M AZ 20 (or DMSO control) for 45min prior to treatment with 
25M SM for 5h.  The activation of CHK1 was then investigated using Western blotting with 
the indicated antibodies.  (B) Quantification of the Western blot data in (A) using ImageJ 
software.  Data is presented as level of Ser296 or Ser317 normalised to total CHK1 and 
represents the mean and standard deviation of three independent experiments. 
 
Fig. 3.  PF 477736 blocks CHK1 activation after exposure to UV and SM.  (A) HCT 116 and 
A549 cells were treated with 20-250nM PF 477736 for 45min prior to treatment with UV for 
1h.  The activation of CHK1 was then investigated using Western blotting with the indicated 
antibodies.  (B) HCT 116 and A549 cells were treated with 100nM PF 477736 for 45min 
prior to treatment with 25M SM for 5h.  The activation of CHK1 was then investigated 
using Western blotting with the indicated antibodies.  (C) Quantification of the Western blot 
data in (B) using ImageJ software.  Data is presented as level of Ser296 or Ser317 normalised 
to total CHK1 and represents the mean and standard deviation of three independent 
experiments. 
 
Fig. 4.  Inhibition of CHK1 enhances SM toxicity.  (A) HCT 116, A549, Hela and HEK 293 
cells were treated with 100nM PF 477736 for 45 min prior to treatment with isopropanol 
(‘untreated control’), 10M SM or 25M SM.  Cell viability was then measured using an 
MTS assay after 24h for HEK 293 cells and 48h for all other cells.  Data is presented as % 
viability relative to untreated cells and represents the mean and standard deviation from three 
independent experiments.  The significance of the observed changes in cell viability between 
DMSO- and PF 477736-treated cells were investigated using a paired t-test.  Levels of 
significance were defined as follows: p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***).  NS = 
not significant.  (B) Hela cells treated as in (A) were analysed by Western blotting with the 
indicated antibodies.  (C) Quantification of the Western blot data in (B) using ImageJ 
software.  Levels of Ser296 and Ser317 were normalised to total CHK1 levels.  The levels of 
all other proteins/phosphorylation sites were normalised to GAPDH.  Data represents the 
mean and standard deviation from three independent experiments. 
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